Abstract
https://www.uniqure.com/assets/uploads/IA-June-2023-Investor-Presentation-06.21.23_Final.pdf
1 clinical trial
1 product
1 drug
1 indication
Clinical trial
A Phase I/II, Randomized, Double-Blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's DiseaseStatus: Recruiting, Estimated PCD: 2029-04-01
Indication
Huntington's diseaseProduct
rAAV5-miHTTDrug
AMT-130